Direct IL-33 injection into cancer patients, generation of human immunogenic cDC1s from CD34+ hematopoietic progenitor cells using IL-33-derived factors, and development of highly immunogenic human Mo-DCs using IL-33-induced factors from human PBMCs are proposed strategies. This evidence concerns the gene IL33 and cancer.